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Defective proliferation and 
osteogenic potential with Altered 
immunoregulatory phenotype of 
native Bone marrow-Multipotential 
Stromal cells in Atrophic fracture 
non-Union
Jehan J. el-Jawhari  1,2,3*, George Kleftouris4, Yasser el-Sherbiny  1,3,5, Hany Saleeb4, 
Robert M. West  6, Elena Jones1 & peter V. Giannoudis  1,2,4
Bone marrow-Multipotential stromal cells (BM-MScs) are increasingly used to treat complicated 
fracture healing e.g., non-union. Though, the quality of these autologous cells is not well characterized. 
We aimed to evaluate bone healing-related capacities of non-union BM-MScs. iliac crest-BM was 
aspirated from long-bone fracture patients with normal healing (U) or non-united (nU). Uncultured 
(native) CD271highCD45low cells or passage-zero cultured BM-MSCs were analyzed for gene expression 
levels, and functional assays were conducted using culture-expanded BM-MSCs. Blood samples were 
analyzed for serum cytokine levels. Uncultured NU-CD271highCD45low cells significantly expressed 
fewer transcripts of growth factor receptors, EGFR, FGFR1, and FGRF2 than U cells. Significant fewer 
transcripts of alkaline phosphatase (ALPL), osteocalcin (BGLAP), osteonectin (SPARC) and osteopontin 
(SPP1) were detected in NU-CD271highCD45low cells. Additionally, immunoregulation-related markers 
were differentially expressed between NU- and U-CD271highCD45low cells. Interestingly, passage-zero 
NU BM-MSCs showed low expression of immunosuppressive mediators. However, culture-expanded 
NU and U BM-MSCs exhibited comparable proliferation, osteogenesis, and immunosuppression. 
Serum cytokine levels were found similar for NU and U groups. Collectively, native NU-BM-MSCs 
seemed to have low proliferative and osteogenic capacities; therefore, enhancing their quality should 
be considered for regenerative therapies. further research on distorted immunoregulatory molecules 
expression in BM-MSCs could potentially benefit the prediction of complicated fracture healing.
Despite advances in trauma fixation techniques within the orthopaedic field, atrophic fracture non-union is still 
significant health and socioeconomic burden1–5. Multipotential stromal cells (BM-MSCs) have been acknowl-
edged for enhancing bone healing particularly in complicated healing conditions such as atrophic fracture 
non-union6–10. However, autologous native BM-MSCs are usually applied as a part of bone marrow (BM) aspi-
rates or concentrate without an assessment of the quality of these cells. Furthermore, inadequate research data on 
the quality of these potential therapeutic cells has led to a lack of consensus on whether complementary growth 
adjuvants are required to enhance their healing capacities.
MSCs can migrate from BM and other adjacent tissues within a few days of bone injury, and are highly 
involved in the three phases of the healing process; inflammatory, repair and remodelling11–14. During the 
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inflammatory phase, a hematoma is formed involving several immune cells and mediators12,13,15–18. However, 
a balanced immune response is required for successful bone healing. A clinical removal of fracture hematoma 
in elderly or multi-diseased patients is perceived as a cause delayed or impaired healing19. Additionally, compli-
cated healing was strongly inked to prolonged local inflammatory response20–22. The presence of MSCs within 
the fracture hematoma has been reported12 with an indication of their involvement in immunosuppression to 
end the inflammatory phase and to start bone repair23. Furthermore, applying MSCs has been linked to decrease 
the levels of inflammatory cytokines in association with enhancing the osteogenesis in experimental models of 
fractures and osteoporosis24–26. However, only MSCs primed by interferon gamma (IFN-γ), tumour necrosis 
factor-alpha (TNF-α), interleukin-1 (IL-1), and interleukin-17 (IL-17) can produce immunosuppressive factors 
such as Tumour Growth Factor-beta 1 (TGF-β1), Prostaglandin E2 (PGE2) and Indoleamine 2,3-Dioxygenase 
(IDO)23.
MSC differentiation into osteoblasts is also essential for bone repair and remodelling. The osteogenic capac-
ity of MSCs typically starts with proliferation and expression of specific proteins, e.g., osteopontin (SPP1), fol-
lowed by matrix maturation with alkaline phosphatase (ALP) expression. Finally, mineralisation is characterised 
by increased ALP and osteocalcin (BGLAP) expression27. Furthermore, MSCs support new bone vasculature 
via Vascular Endothelial Growth Factor (VEGF),28. Recently, Bone Marrow Stromal Cell Antigen-2 (BST2) was 
identified as a marker for some BM-MSC clones with immunoregulatory capacities29. Furthermore, BST2 knock-
down in BM-MSCs has revealed its role in osteogenic differentiation through the regulation of the bone morpho-
genic protein 2 (BMP-2) signalling pathway30. Additionally, another protein related to mineralisation and highly 
expressed in osteoblasts, S100 calcium-binding protein A8 (S100A8) was linked to MSC-mediated immunoreg-
ulation31, but with no link to the MSC osteogenic capacity.
Several studies reported biological mechanisms underlying fracture atrophic non-union development with the 
involvement of the osteogenesis-related BMP and Wnt signalling pathways32–36. However, the research examining 
MSC biology in non-union fracture has been focused on their presence and quantities. These osteoprogenitors 
were detected within the tissues of non-union as expressing stem cell markers36–38. Noteworthy, lower numbers of 
BM-derived colony-forming cells were reported for atrophic non-union than healed fractures patients39; however, 
no difference was found in BM-MSC numbers expressing osteoprogenitor marker, CD271high in another study40. 
Other studies have reported a similar osteogenic function of MSCs resident within non-union tissues relative to 
donor-matched BM-MSCs but without comparison to union-MSCs36,37,41,42. Furthermore, the immunoregula-
tory potential of non-union BM-MSCs is mostly unknown despite being an important part of the bone healing 
process.
We aimed in this study to investigate bone healing-related functions of BM-MSCs in non-united fractures. 
Consequently, we compared proliferation, osteogenesis, and immunoregulation of BM-MSCs from patients who 
had established non-union fractures (NU) with those from patients with united fractures (U). These BM-MSCs 
were analysed either without culture as CD271high CD45low cells, the surrogates of BM-MSCs43–46, or with a 
minimal culture (passage-zero cells). Culture-expansion of these BM-MSCs as standardly characterised47 was 
conducted to generate sufficient cell numbers for the functional assays. To investigate the potential systemic/
serum influence on NU BM-MSC functions, we assessed the serum levels of priming cytokines and their receptor 
expression in BM-MSCs. This knowledge could help to further understand the biological role of MSCs during 
the development of complicated bone healing and potentially aid to optimise the autologous BM-MSC based 
regenerative therapies.
Results
the isolation and characterisation of uncultured BM-cells. To test the functional markers of uncul-
tured (native) BM-MSCs, the FACS isolation of BM-cells (both NU and U) was conducted. The live cells were 
marked as Calceinpositive Aquanegative cells, then CD271high CD45low (MSC surrogates) and CD271negative CD45positive 
cells hematopoietic lineage cells (HLCs) were isolated for gene expression assays (Fig. 1a). Distinct differences 
between CD271high CD45low cells and HLCs were evident as shown via the clustering of transcripts levels and 
comparative group analysis (Fig. 1b and Table 1). As expected, the transcript levels of NGFR (CD271) and oste-
ogenic markers, BGLAP, ALPL, SPARC, LepR and SPP1 were higher for CD271high CD45low cells than HLCs 
(p < 0.0001). Uniquely, more transcripts of IL-1R1 (p = 0.003), Fibroblast growth factor receptors 1 (FGFR1), and 
epidermal growth factor receptor (EGFR) were also detected for CD271high CD45low cells (p < 0.001). However, 
PTPRC (CD45), TGF-ß, Prostaglandin E synthetase 2 (PGES2), IL-17RA, and TNFRS1A transcripts were signif-
icantly lower in CD271high CD45low cells than HLCs (p < 0.0001). Furthermore, IDO and IL-10 transcripts were 
not detected in CD271high CD45low cells. Collectively, uncultured sorted CD271high CD45low cells showed specific 
MSC gene profile compared to HLCs. Based on these findings, we consequently assessed the functional markers 
for sorted CD271high CD45low cells.
A defective proliferation and osteogenic potential of uncultured and minimally-cultured BM-MScs. 
Following the sorting of BM cells, the growth factor receptors and osteogenic markers were tested on isolated 
uncultured CD271high CD45low cells. Interestingly, fewer transcript levels of EGFR, FGFR1 and FGRF2 were 
detected in uncultured NU-CD271high CD45low than U-cells (p = 0.049, p = 0.021, and p < 0.001 respectively, 
Fig. 2a and Table 1) indicating potentially a low response to these growth factors. When measuring the growth 
factors related to angiogenesis, the VEGFA transcripts (but not VEGFC or ANGTP) were lower in NU-CD271high 
CD45low cells than U-cells (p = 0.032, Fig. 2a and Table 1). To test if serum has an impact (systemic) on the pro-
liferation of BM-MSCs, BM cells were seeded in cultures with either NU- or U-serum then the levels of 18 s were 
assessed (without cell passage) as indicative of cell quantities. Noticeably, the donor-matched comparison showed 
that both NU- and U-passage-zero BM-MSCs had reduced 18 s levels when in NU serum cultures than those in 
U-serum cultures (p = 0.031 for both, Fig. 2b) indicating a negative effect of NU serum on MSC proliferation.
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The PCR data showed significantly lower levels of osteogenic markers, ALPL, BGLAP, SPARC and SPP1, but 
not LepR in uncultured NU-CD271high CD45low cells than U-cells (p = 0.040, p = 0.049, p = 0.043 & p = 0.047 
respectively, Fig. 2c and Table 1) suggesting an impaired osteogenic potential for NU BM-MSCs. When cultured 
in NU-serum, passage-zero NU BM-MSCs had consistently less ALPL transcripts relative to U-serum cultures 
(p = 0.008) and U-MSCs in both serum cultures (both p = 0.029, Fig. 2d). However, BGLAP, SPP1 and SPARC tran-
scripts were comparable in both U and NU serum-cultures (Fig. 2d). In summary, reduced the proliferative poten-
tial of NU BM-MSCs was noted, and apparently due to both cellular and serum-related causes. Also, osteogenic 
markers were less expressed on native BM-MSCs, but that was not as evident in serum-supplemented cultures.
Figure 1. The isolation of uncultured BM CD271high CD45low cells. (a) The FACS plots show the gating strategy 
for isolation of live BM cells (as Aqua negative Calcein positive) then uncultured BM-MSCs as CD271high CD45low 
and HLCs (CD45positive CD271negative). (b) The clustering of donor-matched CD271high CD45low and HLCs 
(n = 6) for expression of growth, osteogenic, and immune-related markers. Green: low expression. Red: high 
expression. Grey: below detection.
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An altered immunoregulatory phenotype of uncultured and minimally-cultured nU BM-MScs. To 
assess the immunoregulatory potential of NU BM-MSCs, markers for immunosuppression and other new 
immunoregulation-related molecules were measured. Comparing uncultured NU- and U-CD271high CD45low cells, 
immunosuppressive TGF-β1 and PTGES2 transcripts were found similar (Fig. 3a). These data indicated no difference 
in the basal levels of these immunosuppressive mediators between U- and NU-MSCs. Notably, fewer transcripts of an 
immunoregulation-related marker, BST2 were detected for uncultured NU-CD271high CD45low cells compared to U 
cells (p = 0.019, Fig. 3a and Table 2). In contrast, higher transcript levels of another immunoregulation-related mole-
cule S100A8 (p = 0.022, Fig. 3a and Table 2) were detected for NU-CD271high CD45low cells than U cells. Interestingly, 
the BST2 transcript levels were positively correlated with those of ALPL, BGLAP and SPARC, EGFR, FGFR1 & FGFR2 
(p < 0.001, p = 0.003, p = 0.034, p = 0.012, p = 0.012, p = 0.021, respectively, Fig. 3b). However, S100A8 transcript lev-
els did not correlate with these markers (Fig. 3c). These findings indicated altered immunoregulatory markers of 
NU-MSCs with verification of BST2 link to osteogenic and proliferation of BM-MSCs.
The expression of immunosuppressive markers was further evaluated following treating passage-zero NU 
BM-MSCs with a mixture of IFN-γ, TNF-α, IL-1 and IL-17 in serum-supplemented cultures. Noteworthy, 
cytokine-treated NU BM-MSCs had lower IDO, TGF-β1 and PGES2 expression than U BM-MSCs in their 
matched serum cultures (p = 0.001, p = 0.005, p = 0.001, respectively Fig. 3d). Furthermore, U BM-MSCs were 
found to express fewer transcripts of IDO, TGF-β1, and PGES2 in NU-serum cultures than U-serum cultures 
(p = 0.019, p = 0.019, p = 0.058, respectively Fig. 3d) suggesting an additional effect of NU-serum. Together, NU 
BM-MSCs demonstrated low expression levels of cytokine-induced immunosuppressive markers and particularly 
in NU-serum cultures suggesting both cellular and systemic-related causes.
Functions Gene TaqMan assay Full name
CD271high cells versus 
CD45+ cells (HLCs)
NU CD271high cells 
versus U CD271high cells
Fold Fold
Surface cell markers
NGFR HS00609977_m1 Nerve growth factor receptor (CD271) 1100 (+)* 3.1 (−)*
PTPRC HS00894734_m1 Protein Tyrosine Phosphatase Receptor Type C (CD45) 6.5 (−)* ND
NT5E Hs00159686_m1 5′-Nucleotidase Ecto (CD73) 40.5 (+)* 1.5 (−)
THY1 Hs00174816-m1 Thymus-like antigen 1 (CD90) 53.3 (+)* 2.3 (−)
Growth Factor Receptors
FGFR1 Hs00241111_m1 Fibroblast growth factor receptor 1 108 (+)* 2.2 (−)*
FGFR2 Hs01552926_m1 Fibroblast growth factor receptor 2 ND 2.4 (−)*
EGFR Hs01076078_m1 Epidermal growth factor receptor 26 (+)* 3 (−)*
TGF-βR1 HS00610319_m1 Transforming growth factor beta receptor 1 22 (+))* 1.4 (−)
Angiogenesis related
VEGFA Hs00900058_m1 Vascular endothelial growth factor A 12.6 (+)* 1.5 (−)*
VEGFC Hs01099206_m1 Vascular endothelial growth factor C ND 1.6 (+)
ANGPT1 Hs00181613_m1 Angiopoietin 1 352 (+)* 1.33 (−)
Chondrogenic and 
Adipogenic Differentiation
FABP4 Hs00609791_m1 Fatty acid binding protein 4 ND 1.4 (+)
LepR Hs00174492_m1 Leptin Receptor, encoding CD295protein 197 (+)* 1.5 (+)
SOX9 Hs00165814_m1 SRY (sex-determining region Y)-box 9 ND 1.5 (+)
Osteogenic Differentiation
SPARC Hs00277762_m1 Secreted protein acidic and rich in cysteine 155.7 (+)* 6.3 (−)*
RUNX2 Hs00231692_m1 Runt related transcription factor2 9 (+)* 1.4 (−)
ALPL Hs00758162_m1 Alkaline Phosphatase 2755 (+) * 2.8 (−)*
BGLAP Hs01587814_g1 Bone gamma-carboxy-glutamic acid-containing protein ND 4.8 (−)*
SPP1 Hs00959010_m1 Secreted phosphoprotein 1 (Osteopontin) ND 5.3 (−)*
Cytokine receptors
IL-1R1 Hs00991010_m1 Interleukin-1 receptor 1 215 (+)* 2 (−)*
TNFRS1A Hs01042313_m1 TNF receptor superfamily member 1A (CD120a) 2.5 (−) * 1.1 (−)
IL-17RA Hs01056316_m1 Interleukin 17 receptor A (CD217) 3 (−) * 2 (−)
IFNGR1 Hs00988304_m1 Interferon gamma receptor 1 (CD119) 1.1 (+) 1.4 (−)
Immunosuppressive Factors
IDO Hs00984148_m1 Indoleamine 2,3-dioxygenase ND ND
IL-10 Hs00961622_m1 Interleukin-10 ND ND
PTGES2 Hs00228159_m1 Prostaglandin E synthetase 2 2.3 (−) 1.7 (−)
TGF-β1 Hs00998133_m1 Transforming growth factor beta 1 3 (−)* 1.2 (+)
Immune-related Factors
S100A8 Hs00374264_g1 S100 calcium-binding protein A8 14.5 (−)* 3.4 (+)*
S100A9 Hs00610058_m1 S100 calcium-binding protein A9 90 (+)* 2.5 (−)
BST2 Hs00171632_m1 Bone marrow stromal antigen 2 18.5 (+)* 2.8 (−)*
Housekeeping gene HPRT1 Hs99999909_m1 Hypoxanthine Phosphoribosyl Transferase 1
Table 1. TaqMan markers used in the study and gene expression differences between groups. Comparison 
of CD271high CD45low cells versus CD45positive CD271negative cells (HLCs) was donor-matched (n = 6). 
Comparison of NU CD271high CD45low cells versus U CD271high CD45low cells was not donor-matched (n = 8 
and 9 respectively). *Significant difference p < 0.05. (+): higher expression. (−): lower expression. ND: not 
determined fold difference as the marker gene expression was below detection in one of the groups.
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U and NU BM-MSCs had similar functions when culture-expanded. The uncultured and 
minimally-cultured BM-MSCs showed reduced proliferative capacity, lower expression of osteogenic markers 
with altered expression immunoregulatory markers. To test if these detected changes have a functional impact on 
BM-MSCs, culture expansion of these progenitors was performed to get enough cells for the functional assays. 
The culture-expanded U- and NU BM-MSCs with/without cytokines had no significant differences in the XTT 
absorbance (Fig. 4a) indicating similar in vitro proliferative capacity. To further confirm these data, BM-MSCs 
were loaded on scaffolds, and the numbers of NU- and U-MSCs (counted as CD45− CD73+ CD90+ CD105+ cells 
using flow-cytometry,48) were similarly increased after 3-week cultures relative to 1-week cultures (p = 0.007 and 
p = 0.003 respectively, Fig. 4b) confirming similar proliferation for culture-expanded NU-MSCs and U-MSCs.
For testing the osteogenic differentiation, culture-expanded BM-MSCs were cultured for 3 weeks in osteo-
genic medium with/without cytokine treatment then the calcium deposition levels were measured. While IL-1 
and IL-17 (but not IFN-γ, and TNF-α) seemed to induce calcium levels in differentiating NU and U BM-MSCs 
(Fig. 4c), measured calcium levels were comparable for NU and U BM-MSCs either with or without cytokine 
treatments (Fig. 4c). These data demonstrated the similar osteogenic capacity of culture-expanded NU and U 
BM-MSCs.
For immunosuppression, cytokine-treated culture-expanded MSCs were assessed for the intracellular IDO 
levels using flow-cytometry (Fig. 4d). As expected, the IDO levels were similarly induced when MSCs were treated 
by IFN-γ alone or combined with TNF-α, IL-1 or IL-17 (all p < 0.001, Fig. 4e). Importantly, these induced IDO 
levels were similar for NU- and U-MSCs (Fig. 4e). Also, the percentage of culture-expanded NU- and U-MSCs 
expressing LAP (surface TGF-β1) were similarly increased after cytokine treatments (p = 0.040 p = 0.006, respec-
tively, Fig. 4f). These results indicated comparable immunosuppressive functions of culture-expanded NU- and 
U-MSCs.
Figure 2. The proliferative potential and osteogenic markers of NU BM-MSCs. (a) The figure shows the 
median of relative gene expression of growth factors receptors and angiogenic factors. The unpaired t-test 
was used to compare uncultured isolated NU- CD271high CD45low cells (n = 8) and U-CD271high CD45low cells 
(n = 9). (b) The figure shows the relative gene expression of 18 s for passage-zero NU or U BM-MSCs in cultures 
supplemented with either U-serum or NU-serum. The Wilcoxon test was used to compare passage-zero either 
NU or U BM-MSCs (n = 3) between cultures supplemented with U-serum and NU-serum. (c) The figure shows 
the median of relative gene expression of osteogenic markers. The Mann Whitney test was used to compare 
uncultured isolated NU-CD271high CD45low cells (n = 8) and U-CD271high CD45low cells (n = 9). (d) The figure 
presents the median (with interquartile range) of relative gene expression of osteogenic markers for passage-
zero BM-MSCs in either U-serum or NU-serum supplemented cultures. The Kruskal-Wallis test was used to 
compare the groups (n = 3).
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The expression of cytokine receptors on BM-MSCs and comparable serum cytokine levels dur-
ing early fracture healing. As the minimal cultures data indicated that NU BM-MSCs were less immuno-
suppressive when cytokine-treated compared to U-MSCs, we next tested if the cytokine receptor levels could be 
a contributing factor. Interestingly, the uncultured NU-CD271high CD45low cells expressed fewer transcripts of 
IL-1R1 than U-CD271high CD45low cells (p = 0.005, Fig. 5a). However, no significant differences were detected for 
other cytokine receptor transcripts (Fig. 5a). Consistently, the surface protein expression of the cytokine receptors 
was similar for uncultured NU-and U-CD271high CD45low cells except for IL-1R1, which were less expressed on 
the surface of NU-CD271high CD45low cells (p = 0.049, Fig. 5b).
Figure 3. An altered immunoregulatory phenotype of NU BM-MSCs. (a) The figure shows the median 
of relative gene expression of immunoregulatory markers. The Mann-Whitney test was used to compare 
uncultured isolated NU-CD271high CD45low cells (n = 8) and U-CD271high CD45low cells (n = 9). (b) The 
plots show the correlation between the transcript levels of BST2 versus those of osteogenic and growth factor 
receptors in CD271high CD45low cells. Spearman r test was used for the correlation (n = 17). (c) The plots show 
the correlation between the transcript levels of S100A8 versus those of osteogenic and growth factor receptors 
in CD271high CD45low cells. Spearman r test was used for the correlation (n = 17). (d) The figure presents the 
mean of relative gene expression of IDO, PTGES2 and TGF-β1 when passage-zero BM-MSCs were treated with 
a mixture of IFN-γ, TNF-α, and IL-1 in U-serum or NU-serum supplemented cultures. The Kruskal-Wallis test 







Age median 49 years 44 years 42 years
Age range 18–76 years 20–75 years 23–60 years
Male 16 23 7
Female 6 14 5
Total 22 37 12
Samples BM aspirates and Blood
BM aspirates 
and Blood Blood
Table 2. The study participants. The age and gender for the patients and healthy volunteers included in the 
study with sample types.n
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To explore why contrarily culture-expanded BM-MSCs have similar immunosuppressive functions, the sur-
face cytokine receptor expressions were compared between donor-matched culture-expanded MSCs and uncul-
tured CD271high CD45low cells. The data showed various changes in all receptors surface expression (mainly a 
decrease after culture-expansion) in both U-MSCs and NU-MSCs (Fig. 5c). Furthermore, comparable cytokine 
receptor levels were noted between culture-expanded NU- and U-MSCs (Fig. 5d) verifying changes of MSC sur-
face phenotype during in vitro culture-expansion.
We further aimed to understand if serum cytokines levels are linked to the decreased proliferative potential and 
altered immunosuppressive phenotype of native BM-MSCs. Therefore, the levels of immunosuppression-related 
cytokines were measured in serum of fracture patients relative to control levels. The ELISA data showed that 
IFN-γ, TNF-α, and IL-1 levels were not different between U-sera, NU-sera and control sera (Fig. 6a–c). These 
findings indicated no systemic changes in these cytokine levels during fracture healing. Noteworthy, the meas-
ured IL-17 levels were alike for U and NU fractures during early healing. However, significant lower IL-17 lev-
els were detected for late healing NU-serum than healed U-serum and control levels (p < 0.001 and  p < 0.001, 
respectively, Fig. 6d). Collectively, apart from IL-17 measured in NU serum at late healing, comparable serum 
cytokine levels were noted for NU and U.
Figure 4. The comparison of culture-expanded NU-MSC and U-MSC functions. (a) The Whiskers plot shows 
the median of XTT absorbance (proliferation) for culture-expanded MSCs + /− treatment of inflammatory 
cytokines. The Mann-Whitney test was used to compare U-MSCs (n = 6) & NU-MSCs (n = 4). (b) The figure 
shows the mean (with the standard of the mean) of the MSC numbers released from scaffolds. The paired t-test 
was used for comparing 1-week and 3-week cultures and unpaired t-test for comparing U- and NU-MSCs 
(n = 3). (c) The Whiskers plot presents the median of calcium levels for culture-expanded MSCs following 3 
weeks of culture in an osteogenic medium. The Mann-Whitney test was used to compare U-MSCs (n = 5) and 
NU-MSCs (n = 3). (d) The flow-cytometry plots show the gating of intracellular IDO expression by culture-
expanded MSCs. (e) The mean (with the standard of the mean) of the percentages of positive-expressing 
IDO in culture-expanded MSCs. The paired t-test was used to compare donor-matched no-cytokine with 
cytokines groups. The unpaired t-test was used to compare U-MSCs and NU-MSCs (n = 4). (f) The median of 
the percentages of positive-expressing LAP in culture-expanded MSCs. The paired t-test was used to compare 
donor-matched no-cytokine with cytokines groups. The unpaired t-test was used to compare U-MSCs and NU-
MSCs (n = 4).
8Scientific RepoRtS |         (2019) 9:17340  | https://doi.org/10.1038/s41598-019-53927-3
www.nature.com/scientificreportswww.nature.com/scientificreports/
Discussion
The application of autologous BM to boost the healing of non-united fractures as a source of osteoprogenitors has 
gained lately a great popularity49–52. However, the quality of these BM-MSCs is poorly understood. In this study, 
we comprehensively compared various functional potentials of BM-MSCs from NU and U fracture patients uti-
lising multiple assays and at different cell culture conditions. The functional potential of uncultured CD271high 
CD45low cells and minimal MSC cultures have shown significant differences between NU and U BM-MSCs, 
implying defective multifunction of NU BM-MSC. However, the functions of culture-expanded MSCs were 
similar. This masking of cell differences within the culture-expanded cells is most likely due to in vitro-related 
changes in cell phenotype such as those changes we detected for the expression of the surface cytokine receptors. 
Similarly, adipose-derived MSCs showed significant variations in cell cycle and functional transcripts during 
culture-expansion53. We think that foetal calf serum (FCS) could be a contributing factor to phenotype changes, 
particularly with previous research has shown that human serum, unlike FCS, can maintain the MSC genomic 
patterns54.
With regards to the proliferative capacity, we identified significant lower transcripts levels of EGF and FGF 
receptors for uncultured NU CD271high CD45low cells than U cells. These findings implied a weak response to EGF 
and FGF, which are known to be essential for the MSC proliferation and survival, particularly in fractures55–58. 
Also, a role for EGF in fracture healing has been suggested when its serum levels were found increased in patients 
with a brain injury combined with a limb fracture than those having brain injury only59. In agreement with 
our findings, a previous study has reported downregulation of FGF-R2 gene expression in human non-union 
osteoblast cultures35. In addition to the MSC response to growth factors, we noted an inadequate proliferation 
of passage-zero BM-MSCs in cultures supplemented with NU-serum compared to U-serum cultures inferring 
lower growth inducers in NU-serum. Our group previously showed that the proliferative capacity of BM-MSCs 
from fracture patients was positively correlated with serum growth factor levels, such as platelet-derived growth 
factors (PDGFs)55. In total, it seems that the proliferation of BM-MSCs in non-union patients could be defective 
due to both intrinsic cellular and extrinsic microenvironmental factors. Such complicated alterations of the NU 
Figure 5. The measurements of cytokine receptor expression for BM-MSCs. (a) The scatter dot plots show the 
median of relative gene expression of cytokine receptors. The unpaired t-test was used to compare uncultured 
isolated NU-CD271high CD45low cells (n = 8) and U-CD271high CD45low cells (n = 9) for all cytokine receptors 
except for TNFR1, in which the Mann-Whitney test was used. (b) The scatter dot plots present the median 
of surface expression levels of cytokine receptors. The unpaired t-test was used to compare uncultured NU-
CD271high CD45low cells and U-CD271high CD45low cells (n = 8 and 9 respectively) for all cytokine receptors 
except for CD217 (IL-17RA), in which the Mann-Whitney test was used. (c) The figure demonstrates the 
changes in cytokine receptor levels between donor-matched uncultured CD271high CD45low cells and culture-
expanded MSCs. (d) The figure presents a comparison of cytokine receptor levels between culture-expanded 
NU-MSCs (n = 3) and U-MSCs (n = 6). The Mann-Whitney test was used for the comparison.
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BM-MSC proliferation could be potentially compensated for by applying adequate numbers of BM-MSCs as 
suggested for therapies of non-united fractures51.
We detected significantly lower osteogenic marker levels in uncultured NU BM- CD271high CD45low cells 
despite the osteogenic ability shown for culture-expanded cells in this study and previous work41. In NU-serum 
supplemented cultures, all osteogenic genes, except ALPL showed comparable levels versus U-cultures. These 
observations could be explained by the positive osteoinductive role of human serum effect on progenitor oste-
ogenesis as reported before60. Together, unlike culture-expanded MSCs, our data uniquely suggested a lower 
osteogenic potential of native NU BM-MSCs compared to U BM-MSCs. This apparent osteogenic defect could 
be probably improved by co-application of autologous serum growth factors, e.g., concentrated platelet lysate 
products. Consistent with our findings of low osteogenic potential of BM-MSCs in NU patients, the serum lev-
els of several osteogenic markers have been shown to decrease in NU fractures. Kurdy et al. and Emami et al. 
detected lower levels of ALP in patients with delayed healed tibial fractures than normal healers61,62. Additionally, 
other groups reported reduced levels or delayed induction of osteocalcin levels in NU than U fractures63–65. 
Furthermore, the concentrations of C-terminal cross-linking telopeptide of type I collagen measured in the 
serum of NU patients were significantly less than those in U group66.
Although early inflammatory response is critical for the healing of fractures and bone loss, unbalanced inflam-
mation marked by high levels of cytokines, TNF-α, IFN- γ and IL-1 TNF-α in fracture hematoma or callus could 
hinder a successful bone regeneration and lead to complicated healing (or non-union)11,20,67–69. Schmidt-Bleek 
et al. also have reported that higher relative expression of the pro-inflammatory cytokines together with a higher 
percentage of cytotoxic T cells in the hematoma of delayed healing than those of normal healed fracture70. Several 
Figure 6. The measurements of serum cytokine levels. The figures show the median of serum levels of IFN-
γ, TNF-α, IL-1 and IL-17 (a–d respectively) during a week of fracture (early healing), at or after 6 months of 
fracture (late healing) and healthy control levels (two-time points, 6-month apart). The Kruskal-Wallis test was 
used to compare levels of IFN-γ, TNF-α, IL-1 and IL-17 between U-serum (early healing: n = 9, 12, 9 and 13 
respectively, late healing n = 9, 12, 9 and 11 respectively), NU-serum (early healing n = 5, late healing n = 9, 12, 
9 and 6 respectively) and control serum (both time points: n = 8, 11, 7 and 5 respectively).
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studies reported that MSCs could drive immunosuppressive response as a part of their role in bone healing e.g., 
decreasing cytokines levels in association with enhancing the osteogenesis in fractures or osteoporosis mod-
els24–26. Uniquely, we showed here that NU BM-MSCs had fewer transcripts of IDO, PTGES2 and TGF-β1 when 
cytokine-treated than those of U BM-MSCs. Furthermore, low expression of IL-1 receptors in NU BM-MSCs 
might also suggest less response to such a priming cytokine. Altogether, our findings showed that NU BM-MSCs 
could have less immunosuppressive potential that could negatively affect normal bone healing.
In addition to immunosuppressive markers, other markers related to BM-MSCs immunoregulatory potential 
have been recently described. An example is the detection of high levels of BST2 expression in specific clones of 
BM-MSCs that secrete an immunoregulatory cytokine, IL-629. We also have reported that S100A8 was highly 
expressed on hematopoietic cell-depleted cancellous bone populations that are capable of inhibition of T cell pro-
liferation31. Our novel data here showed that NU BM-MSCs expressed lower BST2 transcripts, but higher S100A8 
transcripts than U BM-MSCs. Furthermore, BTS2, but not S100A8 transcript levels were positively correlated 
with the osteogenic markers and growth receptor levels, confirming previous results of BST2 involvement in the 
MSC osteogenic differentiation30. The high S100A8 transcript levels in NU BM-MSCs could be linked to dysreg-
ulated bone remodelling as S100A8 has been shown as a contributor in the remodelling process71.
We detected significantly lower levels of IL-1 receptors consistently at protein and gene expression levels in 
NU BM-MSCs, also validating our PCR data. Growing evidence has indicated that IL-1 could have an individual 
or additive role to IFN-γ in enhancing MSC-mediated immunosuppression72,73. Additionally, IL-1 was shown to 
enhance osteogenesis, particularly for periodontal ligament stem cells74. Therefore, the functional impact of low 
expression of IL-1R on bone healing would be interesting for further investigations.
We measured the serum levels of cytokines that are known to prime BM-MSCs for immunosuppression. 
Our data showed no differences in serum levels of IFN-γ, TNF-α, IL-1, and IL-17 between patients or healthy 
non-fracture controls. Unlike serum, high levels of TNF-α were noted in fracture hematoma initially, then these 
levels were decreased with repair, but were highly expressed again during remodelling75–77. Also, IFN-γ expres-
sion levels were reported to be increased at hematoma78. Exceptionally, the IL-17 levels in NU-sera were signif-
icantly lower than U- and control serum in late healing. IL-17 was detected in soft callus during bone healing79 
and shown to have a complicated role during remodelling being supportive of osteoblastic bone formation but 
also involved in the stimulation of osteoclasts formation80–82. Our data showing lower IL-17 levels in NU sera 
than controls might suggest a relation to the disturbance in the bone remodelling process. The expression levels 
of several serum cytokines, growth factors, and other inflammation-related molecules in NU fracture patients 
were thoroughly assessed in many previous studies. However, and up to our knowledge, we are the first to com-
pare serum cytokines, IFN-γ, TNF-α, IL-1, and IL-17 between NU, U patients, and healthy controls and found 
comparable levels. Likewise, another study showed that serum levels of IL-8, which is linked to human MSC 
migration83 were not different between NU fractures and controls84. Furthermore, serum levels of other cytokines 
linked to BM-MSC migration, such as Macrophage colony-stimulating factor (M-CSF) and SDF-185, were found 
to be similar between patients with physiological fractures and those with impaired fracture healing84,86. In con-
trast, Mathieu et al. found higher serum levels of IL-6 and lower levels of soluble IL-6 receptors in NU patients 
compared to healthy individuals84. Interestingly, an in vitro work showed that high concentrations of IL-6 with 
low expression of soluble IL-6 receptors could inhibit MSC differentiation87.
In terms of growth factors, TGF-beta, PDGF, FGF, and IGF are critically important for differentiation and 
growth of MSCs58,88. In fractures, TGF-β1 serum levels were found peaked between 1 and 6 weeks after trauma in 
normal healers, but it lasted for a shorter time and lower levels in NU patients89,90. Additionally, reduced PDGF 
serum levels in NU fractures were noted compared to U fractures84,90,91. Similarly, lower serum levels of FGF-2 in 
paediatric NU patients than normal healers were reported92. Previous data also showed low and stable levels of 
serum insulin-like growth factor-1 (IGF-1) and its specific binding proteins in NU fractures84,90,93. While serum 
VEGF concentrations in NU patients were found comparable to those in patients with normal fracture healing 
in some studies84,94, others found that serum VEGF is increased when NU fracture is treated95. Compared to 
systemic changes in these growth factors, other growth factors seemed to have local changes. Serum BMP-2 and 
BMP-4 were below the detection level in both U and NU patients90. Another work demonstrated no significant 
difference in plasma levels of BMP-2, -4, -6, and -7 between patients with NU and those with normal fracture 
healing96. However, the expression levels of these BMPs were significantly lower when assessed within fibrous NU 
tissue relative to a standard healing callus33,97.
Additional serum factors that are related to skeletal tissue inflammation or BM-MSC immunomodulatory 
functions were also quantified by other groups. In one study, NU patients had significantly higher serum con-
centrations of metalloproteinase protein-1 (MMP-1) and MMP-8, which are linked to skeletal tissue inflamma-
tion98 compared with those with normal fracture healing99. S100A9 is also secreted by blood cells, and its high 
serum levels are linked to inflammation, particularly of musculoskeletal tissues100. Interestingly, serum S100A9 
has been found elevated than normal in NU patients101, reflecting a local inflammation of NU tissues in which 
MSCs could be involved. Another work by Wang et al. demonstrated that Nitric oxide (NO), which is linked to 
MSC differentiation and bone remodelling102, had significantly lower levels in persistent NU patients relative to 
those having good healing progress95. Furthermore, proteomic analysis of serum showed that complement C6, 
C3 and C4, which their strongly activating phenotype is less favourable for MSC-related immunosuppression85, 
were up-regulated in the serum of NU patients compared to healthy controls101. Altogether, the systemic changes 
of various serum mediators could explain the lower proliferative and osteogenic potential as well as the altered 
immunomodulatory potential of the MSC pool in BM that we noted in our study and by others for NU fracture 
patients103.
Having NU BM-MSCs collected retrospectively was a limitation in our study. We could not prove that the 
altered immunoregulatory phenotype of these NU BM-MSCs (i.e. being less immunosuppressive, low BST-2 and 
IL-1R and high S100A8 expression) was consistently the same phenotype at the early phase of healing. Further 
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research using a large panel of NU BM-MSCs prospectively collected within the early phase of fracture healing 
would be of great value to confirm our findings of the altered immunoregulatory phenotype. Such research could 
potentially help to introduce new predictive molecules for non-union fracture at the early phase and perhaps 
allowing earlier intervention with therapies to enhance bone repair.
In conclusion, our data of uncultured BM-MSCs indicated some interesting differences between union and 
non-union MSCs. These native NU BM-MSCs seemed to have a low proliferative capacity and osteogenic poten-
tial relative to U BM-MSCs. Additionally, our study is the first report of an altered immunoregulatory phenotype 
of NU BM-MSCs with these cells appeared to have reduced immunosuppressive potential and lower expression 
of BST2. Clinically, the quality of native uncultured autologous BM-MSCs used for enhancing bone regeneration 
should be considered. One may argue that the therapeutic value of autologous native BM-cells could be improved 
with growth adjuvants as well as placing adequate numbers of these BM-MSCs in situ to compensate for poten-
tially low performance.
The functions of culture-expanded NU and U BM-MSCs were comparable most probably due to changes in 
cell phenotype. Therefore, to assess the MSC functions to a close picture as possible to in vivo cell performance, 
functional experiments would need to be optimised on minimally-cultured MSCs and in the presence of human 
serum. In such an experimental approach, future analysis of the functional impact of low IL-1 receptor levels in 
NU BM-MSCs could potentially help to improve cell-based bone regenerative therapies. Additionally, further 
work would be required to confirm a specific immunoregulatory phenotype of NU BM-MSCs at the early healing 
phase, which could potentially help to predict the risk of non-union fractures.
Methods
ethics statement. Informed written consent was obtained from all the study participants before the samples 
were collected, and research was carried out in accordance with the Helsinki Declaration of ethics. The consents 
and sample collection (blood and bone marrow samples used to extract MSCs) for this study were under ethical 
approval with NREC number, 06/Q1206/127, National Research Ethics Committee Yorkshire and Humber–Leeds 
East. All study experiments were conducted according to the appropriate guidelines and regulations.
participants and samples. Overall seventy-one participants were included in the study (Table 2). All 
patients had long bone fractures (femur, tibia, humerus). NU was defined by the absence of radiological fea-
tures of fracture healing (lack of callus formation in at least 3 cortices) either on plane radiographs or computed 
tomography scans after 9 months from fracture fixation and with ongoing pain at the NU site during ambulation. 
Exclusion criteria were children, cancer, diabetes, bone metabolic diseases, inflammatory/immune disorders and 
intake of drugs with a negative impact on fracture healing (i.e. NSAIDs). BM samples (15 ml) were aspirated from 
the anterior iliac crest as previously described104; within one week following injury for U patients, and after diag-
nosis (>9 months) for NU patients. Peripheral venous blood samples (12 ml) were collected (from the patients) 
within one week from the date of fracture (early healing phase) or after fracture had united (4–6 months from 
injury) for U fractures and at the time of NU diagnosis. Serum from healthy individuals who did not have any 
bone fractures was used as control (twice, 6-month apart). Comparing the age of three groups showed no signif-
icant difference (Kruskal-Wallis test, p = 0.497).
isolation of uncultured BM cells and real-time pcR. BM-cells were processed for erythrocyte lysis 
as reported before105 then labelled with CD45 and CD271 antibodies (Miltenyi) and live/dead cell mark-
ers; Calcein violet/Aqua (ThermoFisher) for cell sorting. Uncultured CD271high CD45low cells as surrogates of 
MSCs43–46 and control hematopoietic lineage cells (HLCs, CD271negative CD45positive cells) were isolated using 
Fluorescence-activated cell sorting (FACS, Becton-Dickinson).
The quantitative real-time PCR using TaqMan probes (ThermoFisher, Table 1) was conducted for measur-
ing the relative gene expression levels of chosen markers. RNA extraction was performed as per manufacturer 
recommendation (Norgen Biotek). Extracted RNA samples were processed for reverse transcription and then 
pre-amplification using kits (Fluidigm) as recommended. Finally, the gene expression assays were performed 
using 48.48 chip/Integrated Fluid Circuit (IFC) and using the Biomark™ HD system (Fluidigm). The marker 
transcript levels were calculated relative to that of a housekeeping gene, Hypoxanthine Phosphoribosyl trans-
ferase 1 (HPRT1).
BM-MSc cultures. BM-cells were cultured till plastic-adherent MSCs become confluent then lysed and ana-
lysed without passage (passage-zero cells). These cultures were maintained in DMEM medium (Sigma) supple-
mented with 10% pooled U- or NU-serum (from five donors and collected within one week of fracture). Some 
cultures were treated with cytokines (20 ng/ml IFN-γ, 20 ng/ml TNF-α, 10 ng/ml IL-1 and 100 ng/ml IL-17) as per 
previous studies106–108. For the culture-expansion, BM-cells were maintained in the StemMACS MSC Expansion 
medium (Miltenyi Biotec) and plastic-adherent MSCs were passaged then analysed at passage 3–4.
proliferation. The proliferation of culture-expanded BM-MSCs was assessed using the XTT colorimet-
ric assay kit (Merck). For testing the growth of culture-expanded BM-MSCs on Orthoss collagen® scaffold 
(Geistlich), 10 × 104 cells were loaded on 60 mm2 pieces of the scaffolds for 3 hours before maintaining in cultures. 
The loaded scaffolds were digested after 1 and 3 weeks of culture using collagenase (Stem cell technologies). The 
released cells were then characterised and counted by flow-cytometry as shown previously105,109. For passage-zero 
BM-MSCs in serum-supplemented cultures, the housekeeping 18 S expression was evaluated, indicating cell 
quantities as reported before110.
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osteogenesis and immunosuppression assays. The culture-expanded BM-MSCs were assessed for 
the osteogenesis by measuring the calcium levels after 3 weeks in osteogenic cultures105. The calcium levels were 
measured using a colorimetric kit (Sentinel)105,99,78,78.
The immunosuppressive capacity of culture-expanded BM-MSCs was tested following treatment for 5 
days with cytokines. The cells were then processed for measuring the intracellular IDO and surface TGF-β1 
latency-associated peptide (LAP) levels using specific conjugated monoclonal antibodies (ThermoFisher) 
for flow-cytometer as demonstrated in previous studies111–113. For passage-zero cultured BM-MSCs that were 
cytokine-treated, the expression levels of IDO, PGE2 and TGF-ß transcripts was evaluated indicating the MSC 
immunosuppressive potential.
Surface cytokine receptor measurement. Flow-cytometry was used to measure the cytokine recep-
tor levels on the surface of uncultured NU and U CD271high CD45low cells (and to validate PCR data) or on 
culture-expanded NU and U MSCs. The flow-cytometry conjugated monoclonal antibodies against IFN-γ recep-
tor 1 (CD119), TNF-α receptor 1 (CD120a), (both from Miltenyi Biotec), IL-17 receptor A (CD217), (R&D 
systems) and IL-1β receptor 1 (BD Biosciences) were used for these assays.
Serum cytokine measurements. The blood samples were processed by centrifugation (2000g for 15 min-
utes) to extract the serum, as previously described114. The separated sera were analysed for the IFN-γ, TNF-α, 
IL-1 and IL-17 levels using the hypersensitive ELISA kits (R&D systems) as recommended by the manufac-
turer. The optical density values were acquired using MULTISCAN EX reader and analysed with Ascent software 
(Thermo electron corporation).
Statistical analysis. The statistical analysis and figures’ preparation were performed using GraphPad Prism 
7 software. The Shapiro-Wilk normality test was applied to choose the comparative tests between groups. These 
comparative tests were also applied according to the group numbers and being paired or non-paired; all indicated 
in figure legends. Correlations were tested using the Spearman rho test. Any difference between the groups was 
considered as statistically significant when the p value < 0.05.
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The datasets supporting the conclusions of this study are included within the article and its additional supporting 
file.
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